Ann: FirstFlow Burette market update , page-6

expertspiker

will have to check previous reports. I believe they are in discussions in Europe but may not have exclusivity there

wegian claims were so far off and just a cross promotion. it is not a 50/50 deal at all.

ALT own the product, patent and rights.

MLA are licensed to distribute the product in Australia and New Zealand (perhaps Europe but not exclusively I believe). Any success on the domestic front with QLD Health no doubt benefits both companies tremendously.

However, any success domestically is more than likely a catalyst to larger success internationally in the $3Bn market.

The real players here are Asia, US, Europe and Latin America. ALT is already in discussions in US and Latin America.

If they secure any HOA or clinical trial in US or Latin America, they will receive the lion's share.

I would much rather back the $3Bn market and the company that owns the product over the $88M one and the company that is licensed to distribute.